West Pharmaceutical Services, Inc. (WST)
| Market Cap | 18.32B |
| Revenue (ttm) | 3.07B |
| Net Income (ttm) | 493.70M |
| Shares Out | 72.02M |
| EPS (ttm) | 6.79 |
| PE Ratio | 37.46 |
| Forward PE | 31.89 |
| Dividend | $0.88 (0.35%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 814,350 |
| Open | 247.87 |
| Previous Close | 249.02 |
| Day's Range | 246.78 - 254.40 |
| 52-Week Range | 187.43 - 322.34 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 319.43 (+25.59%) |
| Earnings Date | Feb 12, 2026 |
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, WST's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for WST stock is "Buy." The 12-month stock price target is $319.43, which is an increase of 25.59% from the latest price.
News
Best Dividend Aristocrats For March 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY...
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Feb. 27, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will prese...
West Announces Quarterly Dividend and Share Repurchase Program
EXTON, Pa., Feb. 17, 2026 /PRNewswire/ -- On February 16, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug ad...
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharma forecasts 2026 profit above estimates on strong demand for drug components
West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on strong demand for its proprietary products, which include syringes and ...
West Reports Fourth-Quarter and Full-Year 2025 Results
– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Servi...
West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript
West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript
West to Host Fourth-Quarter and Full-Year 2025 Conference Call
EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will relea...
Time To Buy The Dip In West Pharmaceutical Stock?
West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously b...
West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack
Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in inn...
West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical ...
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company h...
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
West to Participate in Upcoming Investor Conference
EXTON, Pa. , Dec. 12, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Declares Quarterly Dividend
EXTON, Pa. , Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug ad...
Top 50 High-Quality Dividend Growth Stocks For December 2025
I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currentl...
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical: Back To Growth
West Pharmaceutical Services is rated a buy, supported by strong Q3 results, raised guidance, and a resilient long-term growth thesis. WST's focus on high-value proprietary elastomer components and se...
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript
West Pharmaceutical Services, Inc. ( WST) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief ...
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. ( WST) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Robert McMahon - Senior VP & CFO Conference Call Participants ...
West Pharmaceutical Services, Inc. (WST) Presents at UBS Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. ( WST) UBS Global Healthcare Conference 2025 November 11, 2025 9:30 AM EST Company Participants Robert McMahon - Senior VP & CFO Presentation Unknown Analyst Joinin...